Close Menu

NEW YORK (GenomeWeb) – Fulgent Genetics reported after the close of the market on Monday that its second quarter revenues grew 17 percent year over year as billable tests delivered during the quarter climbed 47 percent.

For the three months ended June 30, Fulgent posted $5.4 million in revenues, up from $4.6 million in Q2 2017. The number of billable tests delivered during the recently completed quarter reached 5,700, the company said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jun
04
Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.  

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.